title: Cataract and the use of statins: a case-control study.
abstract: BACKGROUND
  In animal studies, statins have induced cataract formation. Because incident cataract is relatively uncommon, studies in humans have been unable to exclude a clinically important effect.
  
  
  OBJECTIVE
  To assess the risk of cataract associated with the use of statins, and whether it is increased by concurrent use of drugs that inhibit the cytochrome P450 system.
  
  
  METHODS
  Population-based case-control study.
  
  
  METHODS
  Patients were randomly sampled from the UK General Practice Research Database. The study included 15,479 people with cataract and 15,479 controls matched for age, sex, practice and observation period.
  
  
  RESULTS
  The crude odds ratio (OR) for the association between any recorded exposure to statins and cataract was 1.41 (95%CI 1.21-1.65), but this reduced to 1.04 (95%CI 0.89-1.23, p=0.6) after adjustment for consultation rate. There was no evidence that the risk increased with higher doses or longer duration of statin use, or that the risk varied by individual statin. There was no evidence that the risk of cataract was increased by concurrent use of statins and drugs that inhibit the cytochrome P450 system.
  
  
  CONCLUSIONS
  In the short- and medium-term, statins do not seem to be associated with an increased risk of cataract. The need to assess the effects of long-term statin exposure on the eye remains.
authors.affiliation: Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK. liam.smeeth@lshtm.ac.uk
authors.forename: L
authors.initials: L
authors.lastname: Smeeth
authors.forename: R
authors.initials: R
authors.lastname: Hubbard
authors.forename: A E
authors.initials: AE
authors.lastname: Fletcher
mesh_terms: D000368:Aged; D000924:Anticholesteremic Agents / Q000009:adverse effects*; D016022:Case-Control Studies; D002386:Cataract / Q000139:chemically induced*; D065607:Cytochrome P-450 Enzyme Inhibitors; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D016017:Odds Ratio; D011897:Random Allocation; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D000924:Anticholesteremic Agents; D065607:Cytochrome P-450 Enzyme Inhibitors